Insider Trading March 26, 2026

Japan Post Holdings Sells $1.49 Million in Aflac Stock

10% shareholder trims position as Aflac reports mixed Q4 2025 results and Mizuho maintains Underperform

By Sofia Navarro AFL
Japan Post Holdings Sells $1.49 Million in Aflac Stock
AFL

Japan Post Holdings sold 14,000 shares of Aflac on March 24, 2026, generating $1.49 million in proceeds. The transaction was reported on a Form 4 filing with the SEC. Aflac’s recent fourth-quarter 2025 results showed an EPS shortfall versus expectations but a revenue beat; Mizuho adjusted its price target to $107 while keeping an Underperform rating.

Key Points

  • Japan Post Holdings sold 14,000 Aflac shares on March 24, 2026, for a total of $1.49 million at a weighted average price of $106.34 - impacts equity ownership reporting and insider transaction records.
  • After the sale, Japan Post Holdings directly holds 52,032,800 shares of Aflac; the transaction was disclosed in a Form 4 filing with the SEC - relevant to institutional ownership and regulatory transparency.
  • Aflac’s Q4 2025 results were mixed: EPS of $1.57 missed the $1.70 expectation (7.65% negative surprise), while revenue of $4.87 billion exceeded the $4.28 billion forecast (13.79% positive surprise); Mizuho adjusted its target to $107 but kept an Underperform rating, projecting a 6% negative return - relevant to insurance sector outlook and equity analyst sentiment.

Japan Post Holdings Co., Ltd. reported a sale of 14,000 shares of common stock in AFLAC INC (NYSE:AFL) on March 24, 2026, according to a Form 4 filing with the U.S. Securities and Exchange Commission.

The shares were disposed of at a weighted average price of $106.34, producing proceeds of approximately $1.49 million. Transaction prices cited in the filing ranged from $105.93 to $106.845. Following the sale, Japan Post Holdings’ direct stake in Aflac stands at 52,032,800 shares.

At the time of the report, the Aflac share price was trading at $107.72, which the filing notes is close to the stock’s 52-week high of $119.32. Aflac’s market capitalization is listed as $55.49 billion.


Separately, Aflac announced its fourth-quarter 2025 results, posting diluted earnings per share of $1.57 versus an expected $1.70, representing a 7.65% negative surprise relative to consensus estimates. On the top line, the company reported revenue of $4.87 billion, above the forecasted $4.28 billion, a 13.79% positive surprise.

In reaction to the earnings release and subsequent analysis, Mizuho revised its price target for Aflac to $107 from $104 while retaining an Underperform rating on the shares. The firm described the target adjustment as a valuation roll-forward and continues to project a 6% negative return for the stock.

These items were documented in regulatory filings and analyst commentary disclosed alongside Aflac’s quarterly results. The Form 4 filing records the insider sale by Japan Post Holdings, and the earnings and analyst coverage reflect the most recent public financial disclosures for the company.


Summary: Japan Post Holdings sold 14,000 Aflac shares on March 24, 2026 for $1.49 million at a weighted average price of $106.34. Aflac’s Q4 2025 showed an EPS shortfall and a revenue beat. Mizuho moved its price target to $107 while keeping an Underperform rating.

Risks

  • The Form 4 filing documents the sale but does not provide the rationale for Japan Post Holdings’ decision to sell 14,000 shares, leaving the intent and timing unclear - affects interpretation of insider activity in the insurance equity market.
  • Aflac’s EPS for Q4 2025 missed consensus expectations, which could weigh on investor sentiment despite the revenue beat - a risk for the company’s stock performance in the financial and insurance sectors.
  • Mizuho’s maintained Underperform rating and its projection of a 6% negative return for Aflac introduce continued analyst-driven downside risk to the share price; the price-target adjustment reflects valuation mechanics rather than a change to the firm’s stance.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026